Myozyme (Alglucosidase Alfa)

Alglucosidase alfa is a recombinant form of the human acid alpha‑glucosidase enzyme. After intravenous infusion, it is taken up by cells via mannose‑6‑phosphate receptors and delivered to lysosomes, where it hydrolyzes accumulated glycogen, restoring normal glycogen breakdown and reducing cellular storage.

The dose of Myozyme is individualized. The prescribing clinician determines the amount based on factors such as the patient’s body weight, age, disease severity, and clinical response. No fixed regimen is provided here; dosing decisions are made by the treating physician.

Myozyme is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Breastfeeding decisions should be made in consultation with a healthcare professional.

To order Myozyme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Myozyme (alglucosidase alfa) is one of the approved enzyme replacement therapies for Pompe disease. An alternative product, Lumizyme (also alglucosidase alfa but marketed under a different brand), has a similar mechanism and indication. Differences may lie in formulation, packaging, and regional regulatory status, but both aim to replace the deficient enzyme.

Myozyme should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Once reconstituted, the solution should be used promptly according to the product’s handling instructions.

Myozyme is supplied as a lyophilized powder that must be reconstituted with the appropriate diluent to form a solution for injection. The solution is then administered intravenously, typically as an infusion over a period determined by the prescribing clinician.

Serious risks include anaphylaxis, severe hypotension, cardiac arrhythmias, and pulmonary edema. These events are rare but require immediate medical attention. Patients should be monitored closely during and after the infusion for any signs of these reactions.

Myozyme is contraindicated in individuals with a known hypersensitivity to alglucosidase alfa or any of the product’s excipients. Caution is also advised for patients with severe renal impairment or uncontrolled cardiac disease, and the decision to treat should be made by a qualified healthcare professional.